These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30551545)

  • 21. Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model.
    Sano R; Ishii Y; Yamanaka M; Yasui Y; Kemmochi Y; Kuroki F; Sugimoto M; Fukuda S; Sasase T; Miyajima K; Nakae D; Ohta T
    Physiol Res; 2021 Mar; 70(1):45-54. PubMed ID: 33453716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
    van Bommel EJM; Muskiet MHA; van Baar MJB; Tonneijck L; Smits MM; Emanuel AL; Bozovic A; Danser AHJ; Geurts F; Hoorn EJ; Touw DJ; Larsen EL; Poulsen HE; Kramer MHH; Nieuwdorp M; Joles JA; van Raalte DH
    Kidney Int; 2020 Jan; 97(1):202-212. PubMed ID: 31791665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of olmesartan in ameliorating diabetic nephropathy in rats by targeting the AGE/PKC, TLR4/P38-MAPK and SIRT-1 autophagic signaling pathways.
    Abo El-Nasr NME; Saleh DO; Hashad IM
    Eur J Pharmacol; 2022 Aug; 928():175117. PubMed ID: 35752350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats.
    Maheshwari RA; Balaraman R; Sen AK; Seth AK
    Indian J Pharmacol; 2014; 46(6):627-32. PubMed ID: 25538335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy.
    Lee YH; Kim SH; Kang JM; Heo JH; Kim DJ; Park SH; Sung M; Kim J; Oh J; Yang DH; Lee SH; Lee SY
    Am J Physiol Renal Physiol; 2019 Oct; 317(4):F767-F780. PubMed ID: 31390268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia preconditioning increases the ability of healthy but not diabetic rat-derived adipose stromal/stem cells (ASC) to improve histological lesions of streptozotocin-induced diabetic nephropathy.
    Carmona M; Paco-Meza LM; Ortega R; Cañadillas S; Caballero-Villarraso J; Blanco A; Herrera C
    Pathol Res Pract; 2022 Feb; 230():153756. PubMed ID: 35032832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dapagliflozin attenuates renal fibrosis by suppressing angiotensin II/TGFβ signaling in diabetic mice.
    Jiang M; Yang Z; Lyu L; Shi M
    J Diabetes Complications; 2024 Feb; 38(2):108687. PubMed ID: 38266571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin Reduces Urinary Albumin Excretion by Downregulating the Expression of cAMP, MAPK, and cGMP-PKG Signaling Pathways Associated Genes.
    Chen G; Wang H; Zhang W; Zhou J
    Genet Test Mol Biomarkers; 2021 Oct; 25(10):627-637. PubMed ID: 34672772
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats.
    Chen L; LaRocque LM; Efe O; Wang J; Sands JM; Klein JD
    Am J Med Sci; 2016 Nov; 352(5):517-523. PubMed ID: 27865300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
    Akahane K; Inoue T; Yokoyama A; Yaguchi A; Ojima K; Kiguchi S; Maruyama K; Kobayashi M; Mori Y
    Drug Res (Stuttg); 2015 Aug; 65(8):416-21. PubMed ID: 25188606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Dapagliflozin Treatment on the Expression of Renal Sodium Transporters/Channels on High-Fat Diet Diabetic Mice.
    Ma C; de Baaij JHF; Millar PJ; Gault VA; de Galan BE; Bindels RJM; Hoenderop JGJ
    Nephron; 2019; 142(1):51-60. PubMed ID: 30799406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the development of renal injury in Type-1 diabetic Dahl salt-sensitive rats.
    Slaughter TN; Paige A; Spires D; Kojima N; Kyle PB; Garrett MR; Roman RJ; Williams JM
    Am J Physiol Regul Integr Comp Physiol; 2013 Oct; 305(7):R727-34. PubMed ID: 23926133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dapagliflozin attenuates AKI to CKD transition in diabetes by activating SIRT3/PGC1-α signaling and alleviating aberrant metabolic reprogramming.
    Li H; Xia Y; Zha H; Zhang Y; Shi L; Wang J; Huang H; Yue R; Hu B; Zhu J; Song Z
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167433. PubMed ID: 39067538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet-fed streptozotocin-treated diabetic rats.
    Gamil NM; Abd El Fattah MA; Ahmed MAE; Maklad YA; Gamal El Din AA; Eid NI
    J Biochem Mol Toxicol; 2020 Apr; 34(4):e22451. PubMed ID: 31975531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empagliflozin alone and in combination with metformin mitigates diabetes-associated renal complications.
    Madhag Z; Al-Isawi Z
    J Med Life; 2024 May; 17(5):530-535. PubMed ID: 39144694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus.
    Hare GMT; Zhang Y; Chin K; Thai K; Jacobs E; Cazorla-Bak MP; Nghiem L; Wilson DF; Vinogradov SA; Connelly KA; Mazer CD; Evans RG; Gilbert RE
    Physiol Rep; 2021 Jun; 9(12):e14890. PubMed ID: 34184431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
    Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
    Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.